Regular follow-up after curative resection of nonsmall cell lung cancer:: a real benefit for patients?

被引:39
作者
Egermann, U
Jaeggi, K
Habicht, JM
Perruchoud, AP
Dalquen, P
Solèr, M
机构
[1] Univ Hosp, Dept Internal Med, Div Pulm, Basel, Switzerland
[2] Univ Hosp, Inst Pathol, Basel, Switzerland
[3] Univ Hosp, Dept Cardiothorac Surg, Basel, Switzerland
关键词
cost effectiveness; lung cancer; post-operative follow-up;
D O I
10.1183/09031936.02.00231802
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Even though complete resection is regarded as the only curative treatment for nonsmall cell lung cancer (NSCLC), >50% of resected patients die from a recurrence or a second primary tumour of the lung within 5 yrs. It remains unclear, whether follow-up in these patients is cost-effective and whether it can improve the outcome due to early detection of recurrent tumour. The benefit of regular follow-up in a consecutive series of 563 patients, who had undergone potentially curative resection for NSCLC at the University Hospital, was analysed. The follow up consisted of clinical visits and chest radiograph y according to a standard protocol for up to 10 yrs. Survival rates were estimated using the Kaplan-Meier analysis method and the cost-effectiveness of the follow-up programme was assessed. A total of 23 patients (6.4% of the group with lobectomy) underwent further operation with curative intent for a second pulmonary malignancy. The regular follow-up over a 10-yr period provided the chance for a second curative treatment to 3.8% of all patients. The calculated costs per life-yr gained were 90,000 Swiss Francs. The cost-effectiveness of the follow-up protocol was far above those of comparable large-scale surveillance programmes. Based on these data, the intensity and duration of the follow-up was reduced.
引用
收藏
页码:464 / 468
页数:5
相关论文
共 20 条
[1]  
ADEBONOJO SA, 1997, CHEST, V112, P639
[2]  
CLIFTON F, 1997, CHEST, V111, P1711
[3]  
DESCHAMPS C, 1990, J THORAC CARDIOV SUR, V99, P769
[4]   The utility of follow-up testing after curative cancer therapy - A critical review and economic analysis [J].
Edelman, MJ ;
Meyers, FJ ;
Siegel, D .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1997, 12 (05) :318-331
[5]   The economics of lung cancer management in Canada [J].
Evans, WK ;
Will, BP ;
Berthelot, JM ;
Wolfson, MC .
LUNG CANCER, 1996, 14 (01) :19-29
[6]  
GINSBERG RJ, 1989, THORACIC ONCOLOGY, P123
[7]   Second lung cancers in patients after treatment for an initial lung cancer [J].
Johnson, BE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1335-1345
[8]  
Leivo T, 1999, CANCER, V86, P638, DOI 10.1002/(SICI)1097-0142(19990815)86:4<638::AID-CNCR12>3.0.CO
[9]  
2-H
[10]  
MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606